At the time of writing, Arcturus Therapeutics Holdings Inc [ARCT] stock is trading at $20.46, up 4.28%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ARCT shares have gain 18.13% over the last week, with a monthly amount glided 17.86%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Scotiabank started tracking the stock with Sector Outperform rating on May 28, 2025, and set its price target to $32. On January 28, 2025, BTIG Research initiated with a Buy rating and assigned a price target of $41 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $70 on August 12, 2024. Canaccord Genuity initiated its recommendation with a Buy and recommended $90 as its price target on December 13, 2023. William Blair started tracking with a Outperform rating for this stock on July 24, 2023, and assigned it a price target of $71. In a note dated May 11, 2023, H.C. Wainwright upgraded a Buy rating on this stock and boosted its target price from $19 to $51.
For the past year, the stock price of Arcturus Therapeutics Holdings Inc fluctuated between $8.04 and $25.88. Currently, Wall Street analysts expect the stock to reach $43 within the next 12 months. Arcturus Therapeutics Holdings Inc [NASDAQ: ARCT] shares were valued at $20.46 at the most recent close of the market. An investor can expect a potential return of 110.17% based on the average ARCT price forecast.
Analyzing the ARCT fundamentals
According to Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT], the company’s sales were 109.80M for trailing twelve months, which represents an -46.69% plunge. Gross Profit Margin for this corporation currently stands at 0.45% with Operating Profit Margin at -0.62%, Pretax Profit Margin comes in at -0.51%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.25 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT] has a current ratio of 5.90. Also, the Quick Ratio is 5.90, while the Cash Ratio stands at 4.22. Considering the valuation of this stock, the price to sales ratio is 5.06, the price to book ratio is 2.40.
Transactions by insiders
Recent insider trading involved Chivukula Pad, Chief Scientific Officer & COO, that happened on Oct 15 ’24 when 12000.0 shares were sold. Officer, Chivukula Pad completed a deal on Oct 15 ’24 to buy 12000.0 shares.
